Ceftaroline Fosamil
FDA-approved product (powder, intravenous), marketed as Ceftaroline Fosamil, Teflaro.
- Registered studies
- 50+
- Lab records
- 19
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Bacterial disease
- Bacterial infectious disease
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other cephalosporins and penems
- Anti-infective classification
- Classified as an existing antimicrobial.WHO ATC J01DI02
Repurposing investigation
Ceftaroline Fosamil is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.
AI-predicted activity
AI prediction · nothing measured- MRSA75.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli74.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae92.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- M. tuberculosis49.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
- K. pneumoniae: measured active in 13 of 19 lab records
Show the 19 laboratory records, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Ceftaroline Fosamil with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Cetrorelix AcetateExisting use: Ovulation Inhibition, Positive regulation of ovulation63.2% AI-predicted activityagainst MRSA50+ registered studies
- HexachloropheneExisting use: Phenol and derivatives63.2% AI-predicted activityagainst MRSALab records exist3 registered studies
- LorlatinibExisting use: Cancer, Lymphoma, Neoplasm and 1 more63.1% AI-predicted activityagainst MRSA50+ registered studies
- Alectinib HydrochlorideExisting use: Cancer, Neoplasm, Non-small cell lung carcinoma63.0% AI-predicted activityagainst MRSA13 registered studies
- AlpelisibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 2 more63.0% AI-predicted activityagainst MRSA50+ registered studies
- Histrelin AcetateExisting use: Neoplasm, Prostate adenocarcinoma, Prostate cancer62.9% AI-predicted activityagainst MRSA13 registered studies
- Degarelix AcetateExisting use: Prostate adenocarcinoma, Prostate cancer, Prostate carcinoma62.9% AI-predicted activityagainst MRSA50+ registered studies
- Lasmiditan SuccinateExisting use: Migraine disorder62.8% AI-predicted activityagainst MRSANo documented evidence found
- TacrolimusExisting use: Atopic eczema, Delayed Graft Function, Eczematoid dermatitis and 3 more62.5% AI-predicted activityagainst MRSA50+ registered studies
- Rezafungin AcetateExisting use: Candidemia, Candidiasis, Candidiasis, Invasive62.4% AI-predicted activityagainst MRSA5 registered studies
- AvapritinibExisting use: Cancer, Gastrointestinal stromal tumor, Neoplasm62.2% AI-predicted activityagainst MRSA30 registered studies
- Ceruletide DiethylamineExisting use: Tests for bile duct patency62.2% AI-predicted activityagainst MRSANo documented evidence found
Registered studies
A registration describes a study; it does not establish a positive result.
Pharmacokinetics of Ceftaroline in Subjects 12 to 17 Years of Age
NCT00633126 · start 2008-03
Registered record
- Registry ID
- NCT00633126
- Conditions
- Infection
- Interventions
- ceftaroline
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2008-03
- Completion
- 2009-02
- Enrolment
- 9
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInfectionInterventionceftarolinePhasePhase 1Registry statusCompletedEfficacy and Safety of Ceftaroline Versus Linezolid in Subjects With Complicated Skin and Skin Structure Infections
NCT00633152 · start 2008-02
Registered record
- Registry ID
- NCT00633152
- Conditions
- Bacterial Infection
- Interventions
- ceftaroline; linezolid; Aztreonam
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2008-02
- Completion
- 2008-07
- Enrolment
- 150
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBacterial InfectionInterventionceftaroline; linezolid; AztreonamPhasePhase 2Registry statusCompletedComparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia
NCT00621504 · start 2008-01
Registered record
- Registry ID
- NCT00621504
- Conditions
- Bacterial Pneumonia
- Interventions
- Ceftaroline fosamil for Injection; IV Ceftriaxone; Placebo; Clarithromycin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2008-01
- Completion
- 2009-06
- Enrolment
- 606
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBacterial PneumoniaInterventionCeftaroline fosamil for Injection; IV Ceftriaxone; Placebo; ClarithromycinPhasePhase 3Registry statusCompletedComparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections
NCT00423657 · start 2007-03
Registered record
- Registry ID
- NCT00423657
- Conditions
- Bacterial Infections
- Interventions
- ceftaroline; vancomycin plus aztreonam; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2007-03
- Completion
- 2007-12
- Enrolment
- 680
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBacterial InfectionsInterventionceftaroline; vancomycin plus aztreonam; PlaceboPhasePhase 3Registry statusCompletedComparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections
NCT00424190 · start 2007-02
Registered record
- Registry ID
- NCT00424190
- Conditions
- Bacterial Infections
- Interventions
- IV Vancomycin plus IV Aztreonam; Ceftaroline
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2007-02
- Completion
- 2007-11
- Enrolment
- 698
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBacterial InfectionsInterventionIV Vancomycin plus IV Aztreonam; CeftarolinePhasePhase 3Registry statusCompleted